In United States market
Dr Reddy's Laboratories announced that it has received approval from USFDA to launch Doxorubicin Hydrochloride Liposome Injection, a therapeutic equivalent generic version of Doxil, for intravenous use, in the United States market.Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)